<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30183692</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>18</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">1945-6123</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>45</Volume>                    <Issue>1</Issue>                    <PubDate>                        <MedlineDate>Spring 2018</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Journal of registry management</Title>                <ISOAbbreviation>J Registry Manag</ISOAbbreviation>            </Journal>            <ArticleTitle>The Impact of Multiple Primary Rules on Cancer Statistics in Canada, 1992 to 2012.</ArticleTitle>            <Pagination>                <MedlinePgn>8-20</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Several sets of multiple primary rules have been used in Canada to determine whether a cancer is new and little is known of the impact on cancer statistics. We examine the effect of rules on the magnitude and trend of age-standardized incidence rates (ASIRs) of cancer in Canada between 1992 and 2012.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Cancer- and sex-specific ASIRs were estimated using Canadian Cancer Registry (CCR) rules and the more conservative International Agency for Research on Cancer (IARC) rules. CCR- and IARC-based ASIRs and trends were compared using rate ratios (CCR:IARC) and joinpoint analysis, respectively. We highlight instances where CCR-based ASIRs exceed the upper 95% confidence limit of corresponding IARC-based ASIRs, as well as instances where the magnitude and/or direction of annual percent change (APC) in ASIRs differ across rules. Additionally, we examine how differences in CCR- and IARC-based estimates vary across regions.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Between 1992 and 2012, ASIR ratios (CCR:IARC) for all cancers combined increased from about 1 to 1.061 and 1.067 for males and females, respectively, and reached as high as 1.141 for male melanoma and 1.109 for female breast cancer. Between 2010 and 2012, ASIR ratios were elevated for stage 0-1 colorectal (males, 1.060; females, 1.072) and lung and bronchus cancer (males, 1.052; females, 1.061) and all stages of female breast cancer (stage 0-1, 1.100; stage 2, 1.061; stage 3, 1.059; stage 4, 1.094). Where differences existed, CCR-based trends tended to demonstrate steeper increases (eg, male and female melanoma) or less steep declines (eg, all male cancers, female breast cancer). Ontario was particularly impacted and substantially influenced national estimates.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Multiple primary rules can substantially affect the magnitude and trend of ASIRs. The impact will continue to grow as the number of people surviving cancer, and thus at risk for subsequent cancers, continues to grow. Because of inconsistencies in the multiple primary rules used over time, we recommend using IARC rules for monitoring trends and making comparisons across jurisdictions, and using CCR rules for quantifying the full burden of cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Zakaria</LastName>                    <ForeName>Dianne</ForeName>                    <Initials>D</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Registry Manag</MedlineTA>            <NlmUniqueID>9804163</NlmUniqueID>            <ISSNLinking>1945-6131</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>                <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">International Agency for Research on Cancer</Keyword>            <Keyword MajorTopicYN="N">Surveillance, Epidemiology, and End Results (SEER)</Keyword>            <Keyword MajorTopicYN="N">cancer registries</Keyword>            <Keyword MajorTopicYN="N">multiple primary rules</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183692</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>